Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: A frequentist meta-analysis approach

Simone Lanini; Alessia Mammone; Vincenzo Puro; Enrico Girardi; Paolo Bruzzi; Giuseppe Ippolito

Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: A frequentist meta-analysis approach

Simone Lanini, Alessia Mammone, Vincenzo Puro, Enrico Girardi, Paolo Bruzzi, Giuseppe Ippolito

Research output: Contribution to journal › Article › peer-review

Abstract

This meta-analysis assesses the efficacy and safety of triple therapy with either boceprevir or telaprevir compared to the standard of care (SoC), pegylated interferon plus ribavirin, in patients chronically infected with genotype 1 hepatitis C virus (HCV). We included 10 randomized controlled trials comprising 33 individual treatment arms which enrolled 5,312 subjects. Meta-analysis for sustained virologic response (SVR) provided evidence that triple therapy with either boceprevir or telaprevir increased response by 1.76 times (CI-95% 1.63-1.89) in comparison with SoC. However, heterogeneity was strong (I-2 79.7% p for heterogeneity

Original language	English
Pages (from-to)	263-276
Number of pages	14
Journal	New Microbiologica
Volume	37
Issue number	3
Publication status	Published - 2014

Keywords

Adverse event
Boceprevir
Direct-acting antiviral compounds
Experienced patients
Hepatitis C infection
Iatrogenic disease
Naïve patients
Opportunistic infection
Sustained virological response
Telaprevir

ASJC Scopus subject areas

Microbiology (medical)

Cite this

@article{47bdf73251e345aab1a879771a0dbe0e,

title = "Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: A frequentist meta-analysis approach",

abstract = "This meta-analysis assesses the efficacy and safety of triple therapy with either boceprevir or telaprevir compared to the standard of care (SoC), pegylated interferon plus ribavirin, in patients chronically infected with genotype 1 hepatitis C virus (HCV). We included 10 randomized controlled trials comprising 33 individual treatment arms which enrolled 5,312 subjects. Meta-analysis for sustained virologic response (SVR) provided evidence that triple therapy with either boceprevir or telaprevir increased response by 1.76 times (CI-95% 1.63-1.89) in comparison with SoC. However, heterogeneity was strong (I-2 79.7% p for heterogeneity ",

keywords = "Adverse event, Boceprevir, Direct-acting antiviral compounds, Experienced patients, Hepatitis C infection, Iatrogenic disease, Na{\"i}ve patients, Opportunistic infection, Sustained virological response, Telaprevir",

author = "Simone Lanini and Alessia Mammone and Vincenzo Puro and Enrico Girardi and Paolo Bruzzi and Giuseppe Ippolito",

year = "2014",

language = "English",

volume = "37",

pages = "263--276",

journal = "New Microbiologica",

issn = "1121-7138",

publisher = "Luigi Ponzio e figlio Editori",

number = "3",

}

TY - JOUR

T1 - Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia

T2 - A frequentist meta-analysis approach

AU - Lanini, Simone

AU - Mammone, Alessia

AU - Puro, Vincenzo

AU - Girardi, Enrico

AU - Bruzzi, Paolo

AU - Ippolito, Giuseppe

PY - 2014

Y1 - 2014

N2 - This meta-analysis assesses the efficacy and safety of triple therapy with either boceprevir or telaprevir compared to the standard of care (SoC), pegylated interferon plus ribavirin, in patients chronically infected with genotype 1 hepatitis C virus (HCV). We included 10 randomized controlled trials comprising 33 individual treatment arms which enrolled 5,312 subjects. Meta-analysis for sustained virologic response (SVR) provided evidence that triple therapy with either boceprevir or telaprevir increased response by 1.76 times (CI-95% 1.63-1.89) in comparison with SoC. However, heterogeneity was strong (I-2 79.7% p for heterogeneity

AB - This meta-analysis assesses the efficacy and safety of triple therapy with either boceprevir or telaprevir compared to the standard of care (SoC), pegylated interferon plus ribavirin, in patients chronically infected with genotype 1 hepatitis C virus (HCV). We included 10 randomized controlled trials comprising 33 individual treatment arms which enrolled 5,312 subjects. Meta-analysis for sustained virologic response (SVR) provided evidence that triple therapy with either boceprevir or telaprevir increased response by 1.76 times (CI-95% 1.63-1.89) in comparison with SoC. However, heterogeneity was strong (I-2 79.7% p for heterogeneity

KW - Adverse event

KW - Boceprevir

KW - Direct-acting antiviral compounds

KW - Experienced patients

KW - Hepatitis C infection

KW - Iatrogenic disease

KW - Naïve patients

KW - Opportunistic infection

KW - Sustained virological response

KW - Telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84906489796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906489796&partnerID=8YFLogxK

M3 - Article

C2 - 25180842

AN - SCOPUS:84906489796

VL - 37

SP - 263

EP - 276

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 3

ER -

Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: A frequentist meta-analysis approach

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this